Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 3/20 | 0.61 |
| ▸ | COMT | P21964 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 2/20 | 0.31 |
| ▸ | RAB9A | P51151 | 2/20 | 0.31 |
| ▸ | HRH2 | P25021 | 1/20 | 0.30 |
| ▸ | HRH1 | P35367 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16260596 | 0.76 | PIK3CD (1.00) | PIK3CDCOMTNPC1RAB9AHRH2 | |
| SCHEMBL13683796 | 0.72 | PIK3CD (0.32) | PIK3CD | |
| SCHEMBL2001262 | 0.69 | — | — | |
| SCHEMBL1621691 | 0.69 | PIK3CD (0.61) | PIK3CDCOMTSLC2A1NPC1RAB9A | |
| SCHEMBL20438377 | 0.69 | PIK3CD (0.61) | PIK3CDCOMTSLC2A1NPC1RAB9A | |
| SCHEMBL24209746 | 0.69 | PIK3CD (0.61) | PIK3CDCOMTSLC2A1NPC1RAB9A | |
| SCHEMBL26225719 | 0.68 | PIK3CD (0.51) | PIK3CDCOMTMAPTSLC2A1NPC1 | |
| SCHEMBL12027034 | 0.68 | KDM4E (0.31) | PIK3CDMAPT | |
| Hydrochloric Acid SCHEMBL5183545 | 0.67 | — | — | |
| SCHEMBL12530217 | 0.67 | PIK3CD (0.42) | PIK3CDCOMTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | DANA-FARBER CANCER INSTITUTE, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230227433-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-07-20 | — | — | US | disclosed |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-15 | — | — | US | disclosed |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-21 | — | — | US | disclosed |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-06-07 | — | — | US | disclosed |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-26 | — | — | US | disclosed |
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170233411-A1 | THIAZOLYL-CONTAINING COMPOUNDS FOR TREATING PROLIFERATIVE DISEASES | BTK, BCL9L, BCL9 | PIK3CD 813/4885COMT 2053/4885MAPT 4161/4885 |
| US-20180169097-A1 | COMBINATION THERAPY OF TRANSCRIPTION INHIBITORS AND KINASE INHIBITORS | CHUK, BCOR, MYC | PIK3CD 1684/4885COMT 3362/4885MAPT 3025/4885 |
| US-20180110778-A1 | 4,6-PYRIMIDINYLENE DERIVATIVES AND USES THEREOF | CDKL4, CDKL5, PIP5K1A | PIK3CD 31/4885COMT 2591/4885MAPT 1124/4885 |
| US-20230227433-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASE 12 (CDK12) AND USES THEREOF | CDK12, CDK1, CDK13 | PIK3CD 596/4885COMT 1615/4885MAPT 449/4885 |
| US-20180153894-A1 | FUSED BICYCLIC PYRIMIDINE DERIVATIVES AND USES THEREOF | CDK3, CDK14, CDK1 | PIK3CD 52/4885COMT 3567/4885MAPT 807/4885 |
| US-20230183240-A9 | INHIBITORS OF CYCLIN-DEPENDENT KINASES | CDK3, CDK13, CDK1 | PIK3CD 767/4885COMT 1507/4885MAPT 458/4885 |
| US-20230399304-A1 | COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER | CKMT1A; CKMT1B, PHKG1, PCK1 | PIK3CD 1746/4885COMT 797/4885MAPT 4367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.